Contact this trialFirst, we need to learn more about you.
Protein Kinase Inhibitor
Alisertib + Pembrolizumab for Head and Neck Cancer
Recruiting1 awardPhase 1 & 2
Houston, Texas
This trial is investigating the best dose and effect of the drug alisertib when given together with another drug, pembrolizumab, to treat patients with a type of head and neck cancer that is lacking a protein called Rb. Alisertib may help by blocking the growth of cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, helps the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving alisertib together with pembrolizumab may help control Rb-deficient head and neck
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service